US.VRTX · Vertex Pharmaceuticals

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.6,
      "details": {
        "atrPct": 2.221179259950249,
        "turnoverUsdM": 416.83836671999995,
        "liquidityPoints": 0.6,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.VRTX",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 491.7014,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2,
        "rsi_score": 2.5,
        "macd_score": 1.5,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.1,
      "stop_loss_percent": 4.4,
      "take_profit_price": 540.288,
      "target_multiplier": 1.9,
      "technical_strength": 1.68,
      "take_profit_percent": 5
    },
    "positionPoints": 1.6,
    "stopLossPoints": 2.4,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 4.442358519900498,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 48.4,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 45.4,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 3
  },
  "market": {
    "ma20": 538.0425,
    "ma50": 510.3014,
    "close": 514.56,
    "prevClose": 521.12,
    "avgVolume20": 1022259,
    "volumeRatio": 0.79,
    "changePercent": -1.26
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 3,
    "details": {
      "ret_5d": -0.07577907498877423,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 3,
      "vcp_bonus": 0,
      "vol_ratio": 0.7833701606703382,
      "ret_points": 0,
      "vol_points": 0,
      "range_ratio": 0.7333734213976209,
      "volat_points": 0,
      "day_range_pct": 0.01609135960820883,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 3,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 48.4,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 3.8,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 76,
        "contribution": 3.8
      },
      {
        "raw": 6.8,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 34,
        "contribution": 6.8
      },
      {
        "raw": 4.6,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 30.67,
        "contribution": 4.6
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 7.4,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 74,
        "contribution": 7.4
      },
      {
        "raw": 16.8,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 56,
        "contribution": 16.8
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "避免",
    "result": 45.4,
    "details": [
      "基本面分析總分: 3.8/5分",
      "資金流分析總分: 6.8/20分",
      "市場環境分析總分: 4.6/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 7.4/10分",
      "技術信號分析總分: 16.8/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 3.8,
      "資金流": 6.8,
      "市場環境": 4.6,
      "情緒分析": 4,
      "技術信號": 16.8,
      "風險管理": 7.4
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "良好",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.2,
          "epsPoints": 0,
          "roePoints": 0.75,
          "debtPoints": 0.5,
          "marginPoints": 0.75,
          "turnoverUsdM": 416.83836671999995,
          "volumePoints": 0.5,
          "revenuePoints": 0.4,
          "dividendPoints": 0,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 1.6,
          "mfiPoints": 0.8,
          "obvPoints": 1.6,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.VRTX",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 0.8,
            "details": {
              "qqq": {
                "ma20": 716.52749955,
                "ma50": 710.6121986999997,
                "name": "QQQ",
                "close": 708.69,
                "points": 0.4
              },
              "spy": {
                "ma20": 767.5584954500001,
                "ma50": 758.2458016200002,
                "name": "SPY",
                "close": 757.83002,
                "points": 0.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.221179259950249,
          "atrPoints": 3,
          "cciPoints": 0.8,
          "vixPoints": 0,
          "marketTrendPoints": 0.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 2,
              "sentimentScoreRaw": 0.6
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 142065896,
                "url": "https://finnhub.io/api/news?id=dc6b9c0de1cb18f4adbbaae8d2072e6c10c4470bde1c23926c45d8e279d1b90b",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals Incorporated (VRTX) 12th Annual Cantor Fitzgerald Global Healthcare Conference September 10, 2026 2:10 PM EDTCompany...",
                "category": "company",
                "datetime": 1789061828,
                "headline": "Vertex Pharmaceuticals Incorporated (VRTX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript"
              },
              {
                "id": 142048557,
                "url": "https://finnhub.io/api/news?id=e424f98911eddbdb197c2bf9487ec292fb175165fb48d34261681589a6f8256a",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals Incorporated (VRTX) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 4:30 PM EDTCompany ParticipantsConference Call...",
                "category": "company",
                "datetime": 1789013825,
                "headline": "Vertex Pharmaceuticals Incorporated (VRTX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript"
              },
              {
                "id": 141956313,
                "url": "https://finnhub.io/api/news?id=37c79d6938ffbf657fd58e024a3a1549c3f05cda4350c5984c3e1a1621e55abb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $528.9, indicating a -3.15% shift from the previous trading day.",
                "category": "company",
                "datetime": 1788904204,
                "headline": "Vertex Pharmaceuticals (VRTX) Suffers a Larger Drop Than the General Market: Key Insights"
              },
              {
                "id": 141950629,
                "url": "https://finnhub.io/api/news?id=f069ffa7dda8bcb380bcdef6cdcd5e70533772fb71c407df8c60f073a722560b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
                "category": "company",
                "datetime": 1788872403,
                "headline": "Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know"
              },
              {
                "id": 141379819,
                "url": "https://finnhub.io/api/news?id=a64fdd4280f1952b130f8c25d1558be0be050e099e1a656cc74a708d86298213",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1788366612,
                "headline": "Why Is Vertex (VRTX) Up 14.4% Since Last Earnings Report?"
              },
              {
                "id": 141373301,
                "url": "https://finnhub.io/api/news?id=24eef22228eed8ffbd8091caadf478dcbe7eea4e653e52b0d457f9066f730f6f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals stock has delivered strong multi year gains, and current valuation checks suggest the shares now look closer to fairly priced than clearly cheap or clearly expensive. Vertex Pharmaceuticals has returned 184.9% over the past 5 years, which puts extra focus on whether the current price still offers an appealing entry point for new money. Expectations for continued revenue and cash flow growth from its existing treatment portfolio can support today’s valuation, while any...",
                "category": "company",
                "datetime": 1788314840,
                "headline": "Vertex (VRTX) Stock Trades At A Premium On Earnings Yet Looks Fair On Broader Checks"
              },
              {
                "id": 141370006,
                "url": "https://finnhub.io/api/news?id=a7733c47d2e1590ff56be5c3d230685ab1003ec3f5697ae84abc39b54651b637",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "How Vertex Pharmaceuticals Stock Has Been Trading Recently Vertex Pharmaceuticals (VRTX) has drawn fresh investor attention as its share price reached $544.52 at the last close on 1 September 2026. Recent returns show mixed short term moves, with stronger performance over the past 3 months and over the past year. Over the past year, Vertex Pharmaceuticals has combined a strong 90 day share price return of 28.10% with a 1 year total shareholder return of 39.26%. This suggests that recent price...",
                "category": "company",
                "datetime": 1788278907,
                "headline": "Vertex Pharmaceuticals (VRTX) Could Be 3% Undervalued If Its Pipeline Growth Holds"
              },
              {
                "id": 141279342,
                "url": "https://finnhub.io/api/news?id=54e185545576cdb9dc6d734866d58e0390b06540a7324cc4bfacb43aecc1896b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "On July 29, AbCellera Biologics Inc. (NASDAQ:ABCL) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced a strategic collaboration to research, develop, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases. Under the agreement, AbCellera will leverage its proprietary TCE platform to lead discovery, while Vertex will fund all research and development and retain commercialization rights. In return, […]",
                "category": "company",
                "datetime": 1786751639,
                "headline": "Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough?"
              }
            ],
            "raw_source": [
              {
                "id": 142065896,
                "url": "https://finnhub.io/api/news?id=dc6b9c0de1cb18f4adbbaae8d2072e6c10c4470bde1c23926c45d8e279d1b90b",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals Incorporated (VRTX) 12th Annual Cantor Fitzgerald Global Healthcare Conference September 10, 2026 2:10 PM EDTCompany...",
                "category": "company",
                "datetime": 1789061828,
                "headline": "Vertex Pharmaceuticals Incorporated (VRTX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript"
              },
              {
                "id": 142048557,
                "url": "https://finnhub.io/api/news?id=e424f98911eddbdb197c2bf9487ec292fb175165fb48d34261681589a6f8256a",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals Incorporated (VRTX) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 4:30 PM EDTCompany ParticipantsConference Call...",
                "category": "company",
                "datetime": 1789013825,
                "headline": "Vertex Pharmaceuticals Incorporated (VRTX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript"
              },
              {
                "id": 142007995,
                "url": "https://finnhub.io/api/news?id=c0fd25989b866fd49bd22f04e54f51bc43ee5e05487d9d942e61ac0a016cc5bd",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2253107660/image_2253107660.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (VRTX) rated Hold: CF growth is solid but valuation, margin pressure and new-launch execution risks cap upside.",
                "category": "company",
                "datetime": 1788933582,
                "headline": "Vertex Pharmaceuticals: Solid Growth But Valuation Still Requires Flawless Execution"
              },
              {
                "id": 141956192,
                "url": "https://finnhub.io/api/news?id=e8ea867805065cdc3d008f6c42885b5bb3f26ba30cdd600fdc2416102b77fd41",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "The company has tremendous prospects.",
                "category": "company",
                "datetime": 1788906000,
                "headline": "Goldman Sachs Just Added Vertex Pharmaceuticals to Its Conviction List. Here's the Bull Case for the Big Biotech Stock"
              },
              {
                "id": 141956313,
                "url": "https://finnhub.io/api/news?id=37c79d6938ffbf657fd58e024a3a1549c3f05cda4350c5984c3e1a1621e55abb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $528.9, indicating a -3.15% shift from the previous trading day.",
                "category": "company",
                "datetime": 1788904204,
                "headline": "Vertex Pharmaceuticals (VRTX) Suffers a Larger Drop Than the General Market: Key Insights"
              },
              {
                "id": 141954999,
                "url": "https://finnhub.io/api/news?id=eb15958f52568235b27a22c2cecc31a21d7895fc6a2a010595ad690141029be4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "The company had fallen out of investor favor; its recovery was impressive.",
                "category": "company",
                "datetime": 1788903947,
                "headline": "Why CRISPR Therapeutics Stock Rocked the Market Last Month"
              },
              {
                "id": 141952689,
                "url": "https://finnhub.io/api/news?id=b4df56d6015169489daf46666a01566f77be8ab57d8d5bfde1d18d2e1638dc87",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends of the investing world.",
                "category": "company",
                "datetime": 1788886998,
                "headline": "3 Market-Beating Stocks for Long-Term Investors"
              },
              {
                "id": 141949790,
                "url": "https://finnhub.io/api/news?id=688561018bcaa917b9a5a41e8f86658a16787de652ee84aece614728c020f4a0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "CRISPR's expanding pipeline could unlock significantly more value by 2031.",
                "category": "company",
                "datetime": 1788880800,
                "headline": "Where Will CRISPR Therapeutics Stock Be in 5 Years?"
              },
              {
                "id": 141950533,
                "url": "https://finnhub.io/api/news?id=c846e659349dab3d62d3d6577e64f8a483aba13607264797af9de8b6bf3383f4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "FAIRFIELD, Conn., Sept. 08, 2026 (GLOBE NEWSWIRE) -- With just two days remaining before registration closes for HMG Strategy's 18th Annual Boston C-Level Technology Leadership Summit, qualified technology executives are encouraged to secure their seats now while limited seating remains available. The September 10 summit at The Harvard Club of Boston will bring together CIOs, CISOs, CTOs, Chief Digital Officers, Chief AI Officers and other senior technology leaders to discuss AI governance, Agen",
                "category": "company",
                "datetime": 1788877800,
                "headline": "Register Now: Limited Seating Remains for HMG Strategy’s Sept. 10 Boston C-Level Technology Leadership Summit"
              },
              {
                "id": 141950629,
                "url": "https://finnhub.io/api/news?id=f069ffa7dda8bcb380bcdef6cdcd5e70533772fb71c407df8c60f073a722560b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
                "category": "company",
                "datetime": 1788872403,
                "headline": "Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know"
              },
              {
                "id": 141771131,
                "url": "https://finnhub.io/api/news?id=54bd7ced710bb8cc5af628a759507a12394f53b813d5d08ed02199f47fabf0b9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Biotech just staged one of its sharpest reversals in years, and whether you caught it or completely missed it, the same uncomfortable question now sits in front of every portfolio: does the trade still have teeth, or did the easy money already leave?",
                "category": "company",
                "datetime": 1788798125,
                "headline": "IBB Just Beat the S&P 500 by 22 Points in Three Months. Are You Late to the Party?"
              },
              {
                "id": 141509758,
                "url": "https://finnhub.io/api/news?id=81a0a262d8098c7ecccc6216fe28adcb2dd0d073ce0ee2611eab1c23e9613a97",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2289017666/image_2289017666.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "CRISPR Therapeutics' current $5.6B market cap and $1.78B net cash position offer acquisition appeal. Click to know why CRSP is rated a Buy.",
                "category": "company",
                "datetime": 1788588653,
                "headline": "CRISPR Therapeutics: CASGEVY Validates The Platform, Strengthening The Acquisition Case"
              },
              {
                "id": 141454921,
                "url": "https://finnhub.io/api/news?id=2109b2d0a9fc059644620ec0e33e0c12123ced56d7da3cfb25d8902e87fffdc0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "They could both outperform the market over the medium term, but one appears to have a clear edge.",
                "category": "company",
                "datetime": 1788547800,
                "headline": "Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?"
              },
              {
                "id": 141457315,
                "url": "https://finnhub.io/api/news?id=2414382832d556c52b64fe05e026fd53cdd9fc781fe1c3a2947ceb1e922fbc58",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 5.61% on an annualized basis producing an average annual return of 14.84%. Currently, Vertex Pharmaceuticals has a market",
                "category": "company",
                "datetime": 1788519638,
                "headline": "Here's How Much $100 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth Today"
              },
              {
                "id": 141398199,
                "url": "https://finnhub.io/api/news?id=7d4700673f8c4bd5d49c4dd633a427a5be2e161e3222a34260a84ffa2dc540d8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Next Phase of Geophysical Work Advances Priority Targets Following August Technical StudyVANCOUVER, British Columbia, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce plans to undertake a targeted ground gravity survey at its 100%-owned Robinsons River Salt Project (the “Project”), located approximately 35 kilometres south of Stephenville, Newfoundland and Labrador. The survey has been selected as the Co",
                "category": "company",
                "datetime": 1788440400,
                "headline": "Vortex Energy Announces Plans for Ground Gravity Survey at the Robinsons River Salt Project"
              },
              {
                "id": 141400704,
                "url": "https://finnhub.io/api/news?id=d73ec82f651930fbe8adb62766f2b042452f9ee41b03a835b7ab5d39184a3300",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2201019642/image_2201019642.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "My clustering stock screener is giving us a much more interesting macro signal than simply energy stocks are strong. The portfolio is not simply long commodities. It's long capital intensity",
                "category": "company",
                "datetime": 1788437100,
                "headline": "The Market May Be Telling Us We're Entering A Capital Formation Cycle"
              },
              {
                "id": 141384438,
                "url": "https://finnhub.io/api/news?id=ed99b44d8e7d8891342fece7307f49bbacb2555f786e6a5fb9a66f9154a714d3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "We'll know a little more about the company's prospects by the end of the year.",
                "category": "company",
                "datetime": 1788390300,
                "headline": "2 Reasons CRISPR Therapeutics Stock Could Soar in the Final 4 Months of 2026"
              },
              {
                "id": 141379819,
                "url": "https://finnhub.io/api/news?id=a64fdd4280f1952b130f8c25d1558be0be050e099e1a656cc74a708d86298213",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1788366612,
                "headline": "Why Is Vertex (VRTX) Up 14.4% Since Last Earnings Report?"
              },
              {
                "id": 141384429,
                "url": "https://finnhub.io/api/news?id=c010c50ae2579c32161cb38bbb06fd666c9ce9e6bd53e0a53af8df5406f89934",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals has underperformed the Biotech industry over the past year, but analysts are moderately optimistic about the stock’s prospects.",
                "category": "company",
                "datetime": 1788363846,
                "headline": "How Is Vertex Pharmaceuticals' Stock Performance Compared to Other Biotech Stocks?"
              },
              {
                "id": 141380982,
                "url": "https://finnhub.io/api/news?id=65baeaaa7295a12837cd612dfa717f54409a128b38c6d1881b01425069e0e7da",
                "image": "",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "Morgan Stanley  analyst Terence Flynn   reinstates Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and announces $665 price target.",
                "category": "company",
                "datetime": 1788330769,
                "headline": "Morgan Stanley Reinstates Overweight on Vertex Pharmaceuticals, Announces $665 Price Target"
              },
              {
                "id": 141373301,
                "url": "https://finnhub.io/api/news?id=24eef22228eed8ffbd8091caadf478dcbe7eea4e653e52b0d457f9066f730f6f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals stock has delivered strong multi year gains, and current valuation checks suggest the shares now look closer to fairly priced than clearly cheap or clearly expensive. Vertex Pharmaceuticals has returned 184.9% over the past 5 years, which puts extra focus on whether the current price still offers an appealing entry point for new money. Expectations for continued revenue and cash flow growth from its existing treatment portfolio can support today’s valuation, while any...",
                "category": "company",
                "datetime": 1788314840,
                "headline": "Vertex (VRTX) Stock Trades At A Premium On Earnings Yet Looks Fair On Broader Checks"
              },
              {
                "id": 141369724,
                "url": "https://finnhub.io/api/news?id=f978fc668293edf836ceffd17a2107060d64de5dcd451b44084cbb4d2e92d22f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Investing.com -- Goldman Sachs updated its U.S. and European conviction lists for September, adding several new names as it refreshed its highest-conviction ideas heading into the autumn.",
                "category": "company",
                "datetime": 1788287192,
                "headline": "Goldman Sachs refreshes conviction lists on both sides of the Atlantic"
              },
              {
                "id": 141370006,
                "url": "https://finnhub.io/api/news?id=a7733c47d2e1590ff56be5c3d230685ab1003ec3f5697ae84abc39b54651b637",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "How Vertex Pharmaceuticals Stock Has Been Trading Recently Vertex Pharmaceuticals (VRTX) has drawn fresh investor attention as its share price reached $544.52 at the last close on 1 September 2026. Recent returns show mixed short term moves, with stronger performance over the past 3 months and over the past year. Over the past year, Vertex Pharmaceuticals has combined a strong 90 day share price return of 28.10% with a 1 year total shareholder return of 39.26%. This suggests that recent price...",
                "category": "company",
                "datetime": 1788278907,
                "headline": "Vertex Pharmaceuticals (VRTX) Could Be 3% Undervalued If Its Pipeline Growth Holds"
              },
              {
                "id": 141370005,
                "url": "https://finnhub.io/api/news?id=00c6d5f725ed171c400991bf788ad7ad7d33a782f968710442e3357558b8e381",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "The completed acquisition adds PALSONIFY and atumelnant to Vertex’s portfolio, with the two therapies carrying combined peak annual revenue potential of more than $5 billion according to the company. Key Investor TakeawaysVertex Pharmaceuticals (NASDAQ:VRTX) completed its approximately $10 billion equity-value acquisition of Crinetics Pharmaceuticals on September 1, 2026.",
                "category": "company",
                "datetime": 1788278827,
                "headline": "Vertex Completes $10 Billion Crinetics Acquisition, Adding Rare Endocrine Growth Platform"
              },
              {
                "id": 141362091,
                "url": "https://finnhub.io/api/news?id=210bd0168537d1c72b6739cff803f64b6af9cf6fe69a66671729836e2fdb444b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "BOSTON, September 01, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the successful completion of the acquisition of Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases. Vertex also announced the expansion of its executive leadership team, in support of the Company’s continued growth and diversification.",
                "category": "company",
                "datetime": 1788271380,
                "headline": "Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team"
              },
              {
                "id": 141362092,
                "url": "https://finnhub.io/api/news?id=9f042abdb0138ed11ec6c3e48e188597dfbfdda6a1a996e42a1b5a179aabf151",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "OncoC4, Inc., a late clinical-stage biopharmaceutical company developing novel medicines for cancer and neurodegenerative diseases, today announced the appointment of Steve Chen, JD, PhD, as General Counsel.",
                "category": "company",
                "datetime": 1788264000,
                "headline": "OncoC4 Appoints Dr. Steve Chen, JD, PhD as General Counsel"
              },
              {
                "id": 141361158,
                "url": "https://finnhub.io/api/news?id=5b12099e9ae7c4242e7bef5873ed32a358de4627397821a4ec0f041da3a6530c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.",
                "category": "company",
                "datetime": 1788218440,
                "headline": "1 S&P 500 Stock with Exciting Potential and 2 We Ignore"
              },
              {
                "id": 141362094,
                "url": "https://finnhub.io/api/news?id=08922baef08c98700581a8eded622de2d1463417f2cddeb7318364886ec74fa5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "NBIX's Crenessity gains rapid traction in CAH, with sales soaring and low patient penetration leaving room for growth.",
                "category": "company",
                "datetime": 1788197580,
                "headline": "Neurocrine's Crenessity Gains Ground in CAH: How Far Can Sales Go?"
              },
              {
                "id": 141355051,
                "url": "https://finnhub.io/api/news?id=d92b169b63df4d431d6ca4d3e2a910e2a44404564eff749693f603b009075ae3",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/466613278/image_466613278.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "Big Pharma hits new 52-week highs on strong Q2 results; explore why some lag and which healthcare ETF offers best income risk/reward. Click for more and the picks.",
                "category": "company",
                "datetime": 1788173434,
                "headline": "Big Pharma's Comeback Is Here: Winners, Losers, And 4 ETFs"
              },
              {
                "id": 141337932,
                "url": "https://finnhub.io/api/news?id=9e15849a5291795973d1ff60d89173fba9ef89cac40c0b1eef7ddc20906a3b06",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 5.32% on an annualized basis producing an average annual return of 14.56%. Currently, Vertex Pharmaceuticals has a market",
                "category": "company",
                "datetime": 1787855435,
                "headline": "If You Invested $100 In Vertex Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today"
              },
              {
                "id": 141329219,
                "url": "https://finnhub.io/api/news?id=9d227bb9788bbec12f4ada19baf0f9a5b3442ec7c4b503cb31198016994d61bf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "BOSTON, August 26, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in four upcoming investor conferences.",
                "category": "company",
                "datetime": 1787774400,
                "headline": "Vertex to Participate in Upcoming September Investor Conferences"
              },
              {
                "id": 141329210,
                "url": "https://finnhub.io/api/news?id=494fc4a7e7e95660a751b27eb0ae630285a8b5d40336969ed3193c07198cabfc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex's stock is up 15% in a month as strong CF sales, rising non-CF drug revenues and renal pipeline progress boost its growth story.",
                "category": "company",
                "datetime": 1787751180,
                "headline": "Vertex Pharmaceuticals Up 15% in a Month: How to Play the Stock"
              },
              {
                "id": 141329220,
                "url": "https://finnhub.io/api/news?id=2efc1eb2f1504efc935bad39ac81fc43191acc9d8325e302cef134c0b83a88df",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.",
                "category": "company",
                "datetime": 1787736673,
                "headline": "2 Large-Cap Stocks to Research Further and 1 We Question"
              },
              {
                "id": 141329221,
                "url": "https://finnhub.io/api/news?id=bb83f2f0a7c2ff81c357b015f34cc9609eeb516382bc97e2c709c50480540cae",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Inflation affects corporations differently. These two have the tools to navigate the challenge better than most.",
                "category": "company",
                "datetime": 1787584800,
                "headline": "Inflation Is Rising Again. History Says These 2 Stocks Are Among the Smartest Places to Hide"
              },
              {
                "id": 141270357,
                "url": "https://finnhub.io/api/news?id=c860ce08d4e08f9258062cb8d66f67f20b4b52147ffd6129f0e478139ec5544b",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/21/Expert-Sees-Lower-Payments.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "CNBC's Halftime Report Final Trades: Sechan picked ServiceNow (NYSE: NOW), Lebenthal chose Vertex (NASDAQ: VRTX) and Brown recommended Uber (NYSE: UBER).",
                "category": "company",
                "datetime": 1787300370,
                "headline": "Uber, ServiceNow And A Health Care Stock On CNBC’s ‘Final Trades’"
              },
              {
                "id": 141279339,
                "url": "https://finnhub.io/api/news?id=8d9cbc0bd104b45cfccc7cbd2c068ed28335b859cc9c4ef376db8c67375a427e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Don't bet against Vertex Pharmaceuticals in cystic fibrosis.",
                "category": "company",
                "datetime": 1787259000,
                "headline": "Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead"
              },
              {
                "id": 141279340,
                "url": "https://finnhub.io/api/news?id=155b9bfb8c208e5ddbce0b12f61eae388a3c391b302784352be725c1e6ca15da",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals has raced ahead of the market, while analysts continue to give the stock a decidedly optimistic outlook.",
                "category": "company",
                "datetime": 1787213930,
                "headline": "Are Wall Street Analysts Bullish on Vertex Stock?"
              },
              {
                "id": 141265012,
                "url": "https://finnhub.io/api/news?id=6306299bf8c0083ad7ed7398a1dda29d79bf659716d1cdeed57bf18c43632e5c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Pentavere advances from winning the 2024 Prix Galien USA Award to competing internationally among Prix Galien winners from around the world, further validating DARWEN™ AI as a globally recognized healthcare AI platformThe broader 2026 International Prix Galien nominee field includes innovations from many of the world's leading pharmaceutical, biotechnology and medical technology companies, including AstraZeneca, Merck & Co. (MSD), Johnson & Johnson, Pfizer, Sanofi, Regeneron, Roche, Novo...",
                "category": "company",
                "datetime": 1787139000,
                "headline": "HEALWELL AI's DARWEN(TM) AI Platform Nominated for 2026 International Prix Galien, the Global \"Best of the Best\" in Life Sciences Innovation"
              },
              {
                "id": 141279349,
                "url": "https://finnhub.io/api/news?id=5023715a3073c930cbeb889de0d9f0c715e9eb1a27489a9f88dc6339148f07f1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "ANT survey delivers a 3D subsurface view that reinforces the Robinsons River geological model and de-risks the next stage of technical workVANCOUVER, British Columbia, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce the final results of the Ambient Noise Tomography (“ANT”) survey completed at the Company's 100%-owned Robinsons River Salt Project (the “Project”), located approximately 35 kilometres south",
                "category": "company",
                "datetime": 1787058000,
                "headline": "Vortex Energy Announces Final Ambient Noise Tomography Results for the Robinsons River Salt Project"
              },
              {
                "id": 141279350,
                "url": "https://finnhub.io/api/news?id=c16319e9e5a0594ce94d91a58aae67103c60bf48c8111a1e761a7abb904d849e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Businesses with strong free cash flow tend to be more adaptable and resilient. Some of these companies shine bright by using their cash wisely to strengthen their market positions.",
                "category": "company",
                "datetime": 1787050653,
                "headline": "3 Cash-Producing Stocks on Our Watchlist"
              },
              {
                "id": 141279342,
                "url": "https://finnhub.io/api/news?id=54e185545576cdb9dc6d734866d58e0390b06540a7324cc4bfacb43aecc1896b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "On July 29, AbCellera Biologics Inc. (NASDAQ:ABCL) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced a strategic collaboration to research, develop, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases. Under the agreement, AbCellera will leverage its proprietary TCE platform to lead discovery, while Vertex will fund all research and development and retain commercialization rights. In return, […]",
                "category": "company",
                "datetime": 1786751639,
                "headline": "Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough?"
              },
              {
                "id": 141279343,
                "url": "https://finnhub.io/api/news?id=121dbbc0dd24c01e2e2cbe20976d9967255da4cc4f625d608de73f25a3e6e9ee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals stock has delivered a strong 5 year return, yet current checks suggest the market now prices it roughly in line with its fundamentals rather than as an obvious bargain. Recent news around pipeline catalysts and competitive threats keeps the focus on whether that pricing still leaves enough room for missteps. Over the past 5 years, Vertex Pharmaceuticals has returned 158.2%, which puts recent valuation questions in the context of a stock that has already rewarded long...",
                "category": "company",
                "datetime": 1786749229,
                "headline": "Is Vertex Pharmaceuticals (VRTX) Fairly Valued As Pipeline Catalysts Near?"
              },
              {
                "id": 141279344,
                "url": "https://finnhub.io/api/news?id=ad845cd38300618d82185831e5a6bc71375dd3819365cbdfe4d132fbc0e16813",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "The drugmaker should significantly mitigate its most important risk as it develops new products.",
                "category": "company",
                "datetime": 1786742400,
                "headline": "Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More"
              },
              {
                "id": 141279351,
                "url": "https://finnhub.io/api/news?id=68de4dec7cef46611e52bc7bd83708d22013031b64ec4eddd23a06dc1e657631",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (VRTX) has drawn fresh attention after reporting second quarter 2026 results, raising full year revenue guidance to US$13.1b to US$13.2b, and completing a US$1.42b share repurchase program. See our latest analysis for Vertex Pharmaceuticals. The latest updates on guidance and buybacks come after a solid run in Vertex Pharmaceuticals' stock, with a 90 day share price return of 18.19% and a 1 year total shareholder return of 31.48%. This suggests momentum has been...",
                "category": "company",
                "datetime": 1786741725,
                "headline": "Vertex Pharmaceuticals (VRTX) Could Be 8% Undervalued Following Raised 2026 Guidance"
              },
              {
                "id": 141278992,
                "url": "https://finnhub.io/api/news?id=dd9febaaffadd17c6453617b941b5caf27cdeb0d05ef7fba593bec5de3ada72d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Picture three students turning in exams on the same day, covering the same material. Two walk away with high marks. The third has been raising his grades all semester, yet still gets flagged for summer school. That is roughly the dynamic inside the BofA research note on biotech I received on the ...",
                "category": "company",
                "datetime": 1786730820,
                "headline": "BofA biotech scorecard: Two buys and odd one out"
              },
              {
                "id": 141219761,
                "url": "https://finnhub.io/api/news?id=da70f751bbe83141d4f27ef4146624b19996919da2578c396c2740a8e6ab5c54",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 5.35% on an annualized basis producing an average annual return of 14.69%. Currently, Vertex Pharmaceuticals has a market",
                "category": "company",
                "datetime": 1786708843,
                "headline": "$100 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth This Much Today"
              },
              {
                "id": 141216339,
                "url": "https://finnhub.io/api/news?id=c3f0aff57d50e4a1dd7a3be345d26477178a91b70e18cd1e6169d1e527dc0954",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2203426973/image_2203426973.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals' revenue from its cystic fibrosis franchise grew 10% quarter-on-quarter. Click here to see why VRTX stock is a Buy.",
                "category": "company",
                "datetime": 1786700403,
                "headline": "Vertex Pharmaceuticals: I Was Wrong About Its Near-Term Prospects (Rating Upgrade)"
              },
              {
                "id": 141205416,
                "url": "https://finnhub.io/api/news?id=f9ed0860d21fac5b45889bb5f7d101977f12066b6c9bab95f6a065bf9ebbfa7a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "A California biotech just raised $350 million promising to out-perform opioids without the addiction risk, and its auditors were still warning about survival just months ago. Here is what the science and the filings actually show.",
                "category": "company",
                "datetime": 1786628127,
                "headline": "Inside Latigo Biotherapeutics’ IPO: A Non-Opioid Pain Bet Goes Public"
              },
              {
                "id": 141201319,
                "url": "https://finnhub.io/api/news?id=53aa7945d94041f79fc3c71da1078689d1f51f26eefe2f5010464d79b2c6af29",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (VRTX) has multiple potential catalysts coming from its portfolio that provid",
                "category": "company",
                "datetime": 1786546972,
                "headline": "Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says"
              },
              {
                "id": 141201320,
                "url": "https://finnhub.io/api/news?id=94ae668ac83f9d0c31f3ea05ec0b9d4f8d9080150624d1764bb6bc404342d9d4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Cystic fibrosis investors came to learn a harsh lesson on August 10 about how concentrated a market can be: Sionna Therapeutics, Inc. (NASDAQ:SION) shares fell more than 90% following a key trial failure, while Vertex Pharmaceuticals (NASDAQ:VRTX), the company whose drug dominance Sionna was attempting to challenge, surged to new highs. The Pipeline Flop Sionna […]",
                "category": "company",
                "datetime": 1786506091,
                "headline": "One Company’s Clinical Miss Is Another’s Moat: Vertex Rallies as Sionna’s CF Bet Collapses"
              },
              {
                "id": 141201321,
                "url": "https://finnhub.io/api/news?id=6e1eb33508d1e98d3f2908639df7e4bb95e526c95178197694a844bc74661f7f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals’ second quarter reflected strong commercial momentum, with management highlighting the performance of its cystic fibrosis (CF) portfolio and accelerating uptake of newer products like CASGEVY and JOURNAVX. CEO Reshma Kewalramani attributed revenue growth to “the strength of our cystic fibrosis portfolio and the growing contributions from our newer products,” while also emphasizing progress in regulatory and clinical milestones. Management specifically noted that ALYFTREK a",
                "category": "company",
                "datetime": 1786498882,
                "headline": "5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q2 Earnings Call"
              },
              {
                "id": 141195154,
                "url": "https://finnhub.io/api/news?id=3df760a6590509c410b1316b0c369b2cdec8dbbe87802b2bd472f31783084fc2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals, Amylyx Pharmaceuticals, Praxis Precision Medicines and BridgeBio Pharma face major 2026 catalysts, from FDA decisions to late-stage readouts.",
                "category": "company",
                "datetime": 1786456860,
                "headline": "4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year"
              },
              {
                "id": 141181019,
                "url": "https://finnhub.io/api/news?id=25154402fb3d0f222a8033f7866218d6e3ae8c5b8861a9206afa0c14ca55b514",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Revenue hit $3.3 billion with guidance raised on strong newer product growth.",
                "category": "company",
                "datetime": 1786411788,
                "headline": "Vertex (VRTX) Q2 2026 Earnings Call Transcript"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 2,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.6,
            "source_article_count": 53,
            "discarded_article_count": 42
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 16.8,
        "grade": "較差",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 2.7,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 2.7,
            "vcp_reason": "波幅收縮(18.4%→7.8%)；跌縮量(近10日4日)；站上MA50；升放量(近10日2日)；Ready=Y；Confirm=N",
            "vcp_metrics": {
              "up_days": 5,
              "vol_ref": 1167146.6666666667,
              "down_days": 4,
              "vcp_ready": true,
              "above_ma50": true,
              "avg_vol_10": 991600,
              "avg_vol_20": 1034105,
              "avg_vol_30": 1167146.6666666667,
              "range_pct_10": 0.07806666472325872,
              "range_pct_20": 0.11263990593905475,
              "range_pct_30": 0.1841184507151741,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": false,
              "contraction_ok": true,
              "down_shrink_ok": true,
              "up_expand_days": 2,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.8495933101809541,
              "dist_to_20d_high": 0.0815528781793843,
              "down_shrink_days": 4,
              "breakout_level_20d": 560.25,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.42400239856474564
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 1.6,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 0.4
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.6,
            "details": {
              "atrPct": 2.221179259950249,
              "turnoverUsdM": 416.83836671999995,
              "liquidityPoints": 0.6,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.VRTX",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 491.7014,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2,
              "rsi_score": 2.5,
              "macd_score": 1.5,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.1,
            "stop_loss_percent": 4.4,
            "take_profit_price": 540.288,
            "target_multiplier": 1.9,
            "technical_strength": 1.68,
            "take_profit_percent": 5
          },
          "positionPoints": 1.6,
          "stopLossPoints": 2.4,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 4.442358519900498,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.VRTX",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 78.57,
    "atr": {
      "atr": 11.4293,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.22
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": -105.6
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "平衡",
      "score": 4,
      "value": 0.033
    },
    "kdj": {
      "d": 46.97,
      "j": -18.9,
      "k": 25.01,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "超賣或超買風險",
      "score": 2,
      "value": 38.99
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 4,
      "trend": "弱勢",
      "value": 16795213,
      "recentSlope": -11128.7,
      "previousSlope": 294500
    },
    "rsi": 34.86,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 556.0493,
      "position": "SAR喺價上",
      "distancePct": 8.06,
      "previousTrend": "下降"
    },
    "ma50": 510.3014,
    "macd": {
      "macd": 6.977191763601809,
      "trend": "中性偏多",
      "signal": 12.250807751562082,
      "histogram": -5.273615987960273
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 537.5436,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "空升",
      "ratio": 0.79,
      "score": 2,
      "avgVolume": 1022259,
      "currentVolume": 810087
    },
    "derived": {
      "ma20": 538.0425,
      "ma50": 510.3014,
      "prevClose": 521.12,
      "avgVolume10": 989199,
      "avgVolume20": 1022259,
      "changePercent": -1.26,
      "avgVolumeForScore": 1022259
    },
    "ma_cross": {
      "ma20": 538.0425,
      "ma50": 510.3014,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 538.601,
      "prevMa50": 509.9448,
      "spreadPct": 5.44,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 507.1193,
      "upper": 568.9657,
      "position": "中間"
    },
    "rsi_short": 19.2,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.79
    }
  }
}

{
  "close": 514.56,
  "volume": 810087,
  "changePercent": -1.26
}